FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2893072158> ?p ?o ?g. }

• W2893072158 abstract "Objective: Safety and tolerability of onabotulinumtoxinA were assessed in adults with chronic migraine (CM) in the COMPEL study. Background: The COMPEL study was a multicenter, open-label study evaluating efficacy and safety of onabotulinumtoxinA in adults with CM over 9 treatment cycles (108 weeks). Design/Methods: OnabotulinumtoxinA 155 U was administered every 12 weeks. The primary outcome was the reduction in headache day frequency at week 108 compared to baseline. Safety and tolerability, overall and by treatment cycle, were assessed. Any adverse event (AE) with a start day or increase in severity in the period between successive treatments was attributed to the preceding treatment. The safety population consisted of all patients who received ≥1 dose of onabotulinumtoxinA. Results: 716 patients were enrolled; the majority were Caucasian (81.3%) and women (84.8%). The mean (SD) age was 43 (11.3) years. 373 patients (52.1%) completed the study; 343 (47.9%) withdrew, primarily due to withdrawal of consent (n=92, 12.8%), loss to follow-up (n=82, 11.5%), and protocol violation (n=60, 8.4%). OnabotulinumtoxinA significantly reduced headache day frequency (n=715) by 10.7 (6.4) days, P Conclusions: COMPEL study results demonstrated that the incidence of overall AEs and the most common AEs decreased with repeated administration of onabotulinumtoxinA. Study Supported by: Allergan plc Disclosure: Dr. Brin has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Allergan plc. Dr. Brin holds stock and/or stock options in Allergan plc, which sponsored research in which Dr. Brin was involved as an investigator. Dr. Brin holds stock and/or stock options in Allergan plc. Dr. Winner has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Consulting fees/honoraria from Allergan, Amgen, Supernus, has served on the speaker’s bureau for Allergan, Avanir, Supernus. Dr. Winner has received research support from Allergan, Amgen, NuPathe, AstraZeneca, Avanir, Eli Lilly, Novartis. Dr. Blumenfeld has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Served on advisory boards and/or has consulted for Allergan, Pernix, Teva, Avanir, Depomed, and Supernus, and has received funding for travel, speaking, and/or royalty payments from Allergan. Dr. Blumenfeld has received royalty, license fees, or contractual rights payments from For travel, speaking, and/or royalty payments from Allergan. Dr. Eross has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Allergan, Avinar, Depomed, Pernix. Dr. Eross has received compensation for serving on the Board of Directors of Owner and President of Glia Sciences, Inc. Dr. Eross has received research support from Allergan. Dr. Orejudos has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Allergan plc. Dr. Manack Adams has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Allergan plc. Dr. Manack Adams holds stock and/or stock options in Allergan plc, which sponsored research in which Dr. Manack Adams was involved as an investigator. Dr. Manack Adams holds stock and/or stock options in Allergan plc." @default.
• W2893072158 created "2018-10-05" @default.
• W2893072158 creator A5010720314 @default.
• W2893072158 creator A5015730759 @default.
• W2893072158 creator A5020607799 @default.
• W2893072158 creator A5028174247 @default.
• W2893072158 creator A5050252532 @default.
• W2893072158 creator A5088972033 @default.
• W2893072158 date "2018-04-10" @default.
• W2893072158 modified "2023-09-23" @default.
• W2893072158 title "Long-Term Safety and Tolerability of OnabotulinumtoxinA Treatment in Chronic Migraine Patients: COMPEL Analysis by Treatment Cycle (P4.123)" @default.
• W2893072158 hasPublicationYear "2018" @default.
• W2893072158 type Work @default.
• W2893072158 sameAs 2893072158 @default.
• W2893072158 citedByCount "0" @default.
• W2893072158 crossrefType "journal-article" @default.
• W2893072158 hasAuthorship W2893072158A5010720314 @default.
• W2893072158 hasAuthorship W2893072158A5015730759 @default.
• W2893072158 hasAuthorship W2893072158A5020607799 @default.
• W2893072158 hasAuthorship W2893072158A5028174247 @default.
• W2893072158 hasAuthorship W2893072158A5050252532 @default.
• W2893072158 hasAuthorship W2893072158A5088972033 @default.
• W2893072158 hasConcept C10138342 @default.
• W2893072158 hasConcept C120665830 @default.
• W2893072158 hasConcept C121332964 @default.
• W2893072158 hasConcept C126322002 @default.
• W2893072158 hasConcept C162324750 @default.
• W2893072158 hasConcept C197934379 @default.
• W2893072158 hasConcept C2778375690 @default.
• W2893072158 hasConcept C2778541695 @default.
• W2893072158 hasConcept C2908647359 @default.
• W2893072158 hasConcept C2910587157 @default.
• W2893072158 hasConcept C3017619653 @default.
• W2893072158 hasConcept C3018359032 @default.
• W2893072158 hasConcept C61511704 @default.
• W2893072158 hasConcept C71924100 @default.
• W2893072158 hasConcept C99454951 @default.
• W2893072158 hasConceptScore W2893072158C10138342 @default.
• W2893072158 hasConceptScore W2893072158C120665830 @default.
• W2893072158 hasConceptScore W2893072158C121332964 @default.
• W2893072158 hasConceptScore W2893072158C126322002 @default.
• W2893072158 hasConceptScore W2893072158C162324750 @default.
• W2893072158 hasConceptScore W2893072158C197934379 @default.
• W2893072158 hasConceptScore W2893072158C2778375690 @default.
• W2893072158 hasConceptScore W2893072158C2778541695 @default.
• W2893072158 hasConceptScore W2893072158C2908647359 @default.
• W2893072158 hasConceptScore W2893072158C2910587157 @default.
• W2893072158 hasConceptScore W2893072158C3017619653 @default.
• W2893072158 hasConceptScore W2893072158C3018359032 @default.
• W2893072158 hasConceptScore W2893072158C61511704 @default.
• W2893072158 hasConceptScore W2893072158C71924100 @default.
• W2893072158 hasConceptScore W2893072158C99454951 @default.
• W2893072158 hasOpenAccess W2893072158 @default.
• W2893072158 hasRelatedWork W2803840290 @default.
• W2893072158 hasRelatedWork W2806246458 @default.
• W2893072158 hasRelatedWork W2811121788 @default.
• W2893072158 hasRelatedWork W2886869311 @default.
• W2893072158 hasRelatedWork W2887885454 @default.
• W2893072158 hasRelatedWork W2893615962 @default.
• W2893072158 hasRelatedWork W2915221528 @default.
• W2893072158 hasRelatedWork W2950025797 @default.
• W2893072158 hasRelatedWork W2982561889 @default.
• W2893072158 hasRelatedWork W3093820723 @default.
• W2893072158 hasRelatedWork W3102246766 @default.
• W2893072158 hasRelatedWork W3137815397 @default.
• W2893072158 hasRelatedWork W3147125336 @default.
• W2893072158 hasRelatedWork W3186191094 @default.
• W2893072158 hasRelatedWork W3197720978 @default.
• W2893072158 hasRelatedWork W3200119531 @default.
• W2893072158 hasRelatedWork W3204594642 @default.
• W2893072158 hasRelatedWork W3207790455 @default.
• W2893072158 hasRelatedWork W3209959793 @default.
• W2893072158 hasRelatedWork W3210087989 @default.
• W2893072158 hasVolume "90" @default.
• W2893072158 isParatext "false" @default.
• W2893072158 isRetracted "false" @default.
• W2893072158 magId "2893072158" @default.
• W2893072158 workType "article" @default.